We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-1.43%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$395M
AUM Growth
-$219M
Cap. Flow
-$156M
Cap. Flow %
-39.58%
Top 10 Hldgs %
44.14%
Holding
133
New
27
Increased
24
Reduced
29
Closed
30

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.2M
2
CELG
Celgene Corp
CELG
+$7.8M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$5.42M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.26M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.79M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.1M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
BIIB icon
Biogen
BIIB
+$15.7M
4
PFE icon
Pfizer
PFE
+$14.4M
5
AMGN icon
Amgen
AMGN
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 5.44%
3 Communication Services 2.79%
4 Industrials 1.83%
5 Consumer Discretionary 1.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KITE
51
DELISTED
Kite Pharma, Inc.
KITE
$2.24M 0.57%
50,000
– –
ARDX icon
52
Ardelyx
ARDX
$1.22B
$2.16M 0.55%
151,813
– –
PRTK
53
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.16M 0.55%
140,000
– –
AVXS
54
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.15M 0.54%
45,000
-55,000
-55% -$2.94M
VTGN icon
55
VistaGen Therapeutics
VTGN
$9.89M
$2.03M 0.51%
18,137
– –
FPRX
56
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2M 0.51%
40,000
-20,000
-33% -$1.05M
ALDX icon
57
Aldeyra Therapeutics
ALDX
$92.9M
$1.97M 0.5%
368,500
– –
SNA icon
58
Snap-on
SNA
$21.2B
$1.88M 0.48%
10,972
-7,158
-39% -$1.16M
PDSB icon
59
PDS Biotechnology
PDSB
$38.4M
$1.88M 0.47%
7,500
– –
FWP
60
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.82M 0.46%
17,357
– –
GBT
61
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.81M 0.46%
+125,000
New +$2.2M
MGNX icon
62
MacroGenics
MGNX
$235M
$1.66M 0.42%
81,200
-48,800
-38% -$1.23M
PTCT icon
63
PTC Therapeutics
PTCT
$5.64B
$1.64M 0.41%
+150,000
New +$1.57M
PCRX icon
64
Pacira BioSciences
PCRX
$1.04B
$1.61M 0.41%
+50,000
New +$1.67M
TSEM icon
65
Tower Semiconductor
TSEM
$24.8B
$1.6M 0.4%
+83,940
New +$1.45M
SPNS
66
DELISTED
Sapiens International
SPNS
$1.57M 0.4%
109,322
+28,478
+35% +$400K
CTSH icon
67
Cognizant
CTSH
$24.9B
$1.56M 0.4%
+27,875
New +$1.49M
ORBK
68
DELISTED
Orbotech Ltd
ORBK
$1.51M 0.38%
45,221
-70,881
-61% -$2.17M
META icon
69
Meta Platforms (Facebook)
META
$1.42T
$1.5M 0.38%
+13,062
New +$1.6M
PTN
70
Palatin Technologies
PTN
$13.7M
$1.48M 0.37%
2,325
+800
+52% +$557K
ATXS
71
DELISTED
Astria Therapeutics
ATXS
$1.4M 0.35%
6,466
– –
AZN icon
72
AstraZeneca
AZN
$263B
$1.37M 0.35%
25,000
-75,000
-75% -$4.26M
MRNS
73
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.35M 0.34%
335,147
– –
BA icon
74
Boeing
BA
$171B
$1.31M 0.33%
+8,392
New +$1.23M
RPRX
75
DELISTED
Repros Therapeutics Inc.
RPRX
$1.29M 0.33%
978,800
+114,993
+13% +$200K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sphera Funds Management held 133 positions worth $395M, down 36% from $614M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sphera Funds Management withdrew a net $156M in Q4 2016, closing 30 positions and reducing 29 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in BioMarin Pharmaceuticals worth $3.73M.

  • Sphera Funds Management's largest Q4 2016 buy was BioMarin Pharmaceuticals: 45,000 shares worth $3.73M.
  • Sphera Funds Management added most to Merck in Q4 2016, an estimated $9.2M increase.
  • Sphera Funds Management's biggest Q4 2016 reduction was Achaogen Inc, cutting an estimated $5.39M.
  • Sphera Funds Management fully exited Allergan plc in Q4 2016, selling an estimated $16.1M.
  • Sphera Funds Management's ten largest holdings make up 44% of its $395M portfolio in Q4 2016.
  • Sphera Funds Management opened 27 new positions and closed 30 in Q4 2016.
  • Sphera Funds Management's portfolio value fell 36% quarter-over-quarter to $395M.

Based on Sphera Funds Management's 13F filing for Q4 2016, filed 13 Feb 2017.